{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T23:43:10Z","timestamp":1792194190934,"version":"4.4.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T00:00:00Z","timestamp":1721692800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T00:00:00Z","timestamp":1721692800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s11033-024-09787-w","type":"journal-article","created":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T12:19:01Z","timestamp":1721737141000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Genotypic variation in CYP2E1, GCKR, and PNPLA3 among nonalcoholic steatohepatitis patients of Turkish origin"],"prefix":"10.1007","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8861-7106","authenticated-orcid":false,"given":"Abbas Ali","family":"Husseini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,23]]},"reference":[{"key":"9787_CR1","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1001\/jama.2020.2298","volume":"323","author":"AC Sheka","year":"2020","unstructured":"Sheka AC, Adeyi O, Thompson J et al (2020) Nonalcoholic Steatohepatitis. JAMA 323:1175. https:\/\/doi.org\/10.1001\/jama.2020.2298","journal-title":"JAMA"},{"key":"9787_CR2","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s12664-022-01263-2","volume":"41","author":"F Ghadiri","year":"2022","unstructured":"Ghadiri F, Husseini AA, \u00d6zta\u015f O (2022) A machine-learning approach for nonalcoholic steatohepatitis susceptibility estimation. Indian J Gastroenterol 41:475\u2013482. https:\/\/doi.org\/10.1007\/s12664-022-01263-2","journal-title":"Indian J Gastroenterol"},{"key":"9787_CR3","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1097\/HEP.0000000000000607","volume":"79","author":"ME Rinella","year":"2024","unstructured":"Rinella ME, Lieu HD, Kowdley KV et al (2024) A randomized, double-blind, placebo-controlled trial of aldafermin in patients with NASH and compensated cirrhosis. Hepatology 79:674\u2013689. https:\/\/doi.org\/10.1097\/HEP.0000000000000607","journal-title":"Hepatology"},{"key":"9787_CR4","doi-asserted-by":"publisher","first-page":"R240","DOI":"10.1530\/EC-21-0048","volume":"10","author":"K Kabarra","year":"2021","unstructured":"Kabarra K, Golabi P, Younossi ZM (2021) Nonalcoholic steatohepatitis: global impact and clinical consequences. Endocr Connect 10:R240\u2013R247. https:\/\/doi.org\/10.1530\/EC-21-0048","journal-title":"Endocr Connect"},{"key":"9787_CR5","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13098-022-00976-w","volume":"15","author":"Z Li","year":"2023","unstructured":"Li Z, Yang N, He L et al (2023) Estimates and trends of the global burden of NASH-related liver cancer attributable to high fasting plasma glucose in 1990\u20132019: analysis of data from the 2019 global burden of Disease Study. Diabetol Metab Syndr 15:6. https:\/\/doi.org\/10.1186\/s13098-022-00976-w","journal-title":"Diabetol Metab Syndr"},{"key":"9787_CR6","doi-asserted-by":"publisher","first-page":"865","DOI":"10.5152\/tjg.2019.18045","volume":"30","author":"E Kaya","year":"2019","unstructured":"Kaya E, Yilmaz Y (2019) Non-alcoholic fatty liver disease: a growing public health problem in Turkey. Turkish J Gastroenterol 30:865\u2013871. https:\/\/doi.org\/10.5152\/tjg.2019.18045","journal-title":"Turkish J Gastroenterol"},{"key":"9787_CR7","doi-asserted-by":"publisher","first-page":"892","DOI":"10.5152\/tjg.2019.19072","volume":"30","author":"Y Yilmaz","year":"2019","unstructured":"Yilmaz Y, Kani HT, Demirtas CO et al (2019) Growing burden of nonalcoholic fatty liver disease in Turkey: a single-center experience. Turkish J Gastroenterol 30:892\u2013898. https:\/\/doi.org\/10.5152\/tjg.2019.19072","journal-title":"Turkish J Gastroenterol"},{"key":"9787_CR8","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1136\/flgastro-2013-100403","volume":"5","author":"JK Dyson","year":"2014","unstructured":"Dyson JK, Anstee QM, McPherson S (2014) Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging. Frontline Gastroenterol 5:211\u2013218. https:\/\/doi.org\/10.1136\/flgastro-2013-100403","journal-title":"Frontline Gastroenterol"},{"key":"9787_CR9","doi-asserted-by":"publisher","first-page":"145754","DOI":"10.1155\/2012\/145754","volume":"2012","author":"M Obika","year":"2012","unstructured":"Obika M, Noguchi H (2012) Diagnosis and evaluation of nonalcoholic fatty liver disease. Exp Diabetes Res 2012:145754. https:\/\/doi.org\/10.1155\/2012\/145754","journal-title":"Exp Diabetes Res"},{"key":"9787_CR10","doi-asserted-by":"publisher","first-page":"4835","DOI":"10.3748\/wjg.v24.i43.4835","volume":"24","author":"U Vespasiani-Gentilucci","year":"2018","unstructured":"Vespasiani-Gentilucci U, Gallo P, Dell\u2019Unto C et al (2018) Promoting genetics in non-alcoholic fatty liver disease: combined risk score through polymorphisms and clinical variables. World J Gastroenterol 24:4835\u20134845. https:\/\/doi.org\/10.3748\/wjg.v24.i43.4835","journal-title":"World J Gastroenterol"},{"key":"9787_CR11","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1053\/j.gastro.2021.07.049","volume":"161","author":"F Kanwal","year":"2021","unstructured":"Kanwal F, Shubrook JH, Adams LA et al (2021) Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease. Gastroenterology 161:1657\u20131669. https:\/\/doi.org\/10.1053\/j.gastro.2021.07.049","journal-title":"Gastroenterology"},{"key":"9787_CR12","doi-asserted-by":"publisher","unstructured":"Lonardo A (2023) Principles of risk stratification in nonalcoholic fatty liver disease. A narrative review emphasizing non-invasive strategies. Explor Dig Dis 188\u2013201. https:\/\/doi.org\/10.37349\/edd.2023.00026","DOI":"10.37349\/edd.2023.00026"},{"key":"9787_CR13","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1586\/egh.10.56","volume":"4","author":"LA Adams","year":"2010","unstructured":"Adams LA, Feldstein AE (2010) Nonalcoholic steatohepatitis: risk factors and diagnosis. Expert Rev Gastroenterol Hepatol 4:623\u2013635. https:\/\/doi.org\/10.1586\/egh.10.56","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"9787_CR14","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.3350\/cmh.2022.0367","volume":"29","author":"C Gofton","year":"2023","unstructured":"Gofton C, Upendran Y, Zheng M-H, George J (2023) MAFLD: how is it different from NAFLD? Clin Mol Hepatol 29:S17\u2013S31. https:\/\/doi.org\/10.3350\/cmh.2022.0367","journal-title":"Clin Mol Hepatol"},{"key":"9787_CR15","doi-asserted-by":"publisher","first-page":"e0185490","DOI":"10.1371\/journal.pone.0185490","volume":"13","author":"T Kawaguchi","year":"2018","unstructured":"Kawaguchi T, Shima T, Mizuno M et al (2018) Risk estimation model for nonalcoholic fatty liver disease in the Japanese using multiple genetic markers. PLoS ONE 13:e0185490. https:\/\/doi.org\/10.1371\/journal.pone.0185490","journal-title":"PLoS ONE"},{"key":"9787_CR16","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1053\/j.gastro.2016.01.037","volume":"150","author":"QM Anstee","year":"2016","unstructured":"Anstee QM, Seth D, Day CP (2016) Genetic factors that affect risk of alcoholic and nonalcoholic fatty liver disease. Gastroenterology 150:1728\u20131744e7. https:\/\/doi.org\/10.1053\/j.gastro.2016.01.037","journal-title":"Gastroenterology"},{"key":"9787_CR17","doi-asserted-by":"publisher","first-page":"e87523","DOI":"10.1371\/journal.pone.0087523","volume":"9","author":"S Petta","year":"2014","unstructured":"Petta S, Miele L, Bugianesi E et al (2014) Glucokinase regulatory protein gene polymorphism affects liver fibrosis in non-alcoholic fatty liver disease. PLoS ONE 9:e87523. https:\/\/doi.org\/10.1371\/journal.pone.0087523","journal-title":"PLoS ONE"},{"key":"9787_CR18","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.jhep.2012.08.018","volume":"58","author":"T-M Leung","year":"2013","unstructured":"Leung T-M, Nieto N (2013) CYP2E1 and oxidant stress in alcoholic and non-alcoholic fatty liver disease. J Hepatol 58:395\u2013398. https:\/\/doi.org\/10.1016\/j.jhep.2012.08.018","journal-title":"J Hepatol"},{"key":"9787_CR19","doi-asserted-by":"publisher","first-page":"2925","DOI":"10.1111\/jgh.15554","volume":"36","author":"H Ma","year":"2021","unstructured":"Ma H, Chen S, Zheng KI et al (2021) TA allele of rs2070673 in the CYP2E1 gene is associated with lobular inflammation and nonalcoholic steatohepatitis in patients with biopsy-proven nonalcoholic fatty liver disease. J Gastroenterol Hepatol 36:2925\u20132934. https:\/\/doi.org\/10.1111\/jgh.15554","journal-title":"J Gastroenterol Hepatol"},{"key":"9787_CR20","doi-asserted-by":"publisher","first-page":"10240","DOI":"10.1038\/s41598-019-46750-3","volume":"9","author":"L Fernandes Silva","year":"2019","unstructured":"Fernandes Silva L, Vangipurapu J, Kuulasmaa T, Laakso M (2019) An intronic variant in the GCKR gene is associated with multiple lipids. Sci Rep 9:10240. https:\/\/doi.org\/10.1038\/s41598-019-46750-3","journal-title":"Sci Rep"},{"key":"9787_CR21","unstructured":"NEB (2020) PCR Protocol for Taq DNA Polymerase with Standard Taq Buffer (M0273)"},{"key":"9787_CR22","doi-asserted-by":"publisher","first-page":"13406","DOI":"10.3390\/ijms241713406","volume":"24","author":"LAP Faccioli","year":"2023","unstructured":"Faccioli LAP, Cetin Z, Kocas-Kilicarslan ZN et al (2023) Evaluation of human hepatocyte drug metabolism carrying high-risk or Protection-Associated Liver Disease Genetic variants. Int J Mol Sci 24:13406. https:\/\/doi.org\/10.3390\/ijms241713406","journal-title":"Int J Mol Sci"},{"key":"9787_CR23","doi-asserted-by":"publisher","first-page":"2","DOI":"10.21037\/tgh.2019.09.06","volume":"6","author":"NS Choudhary","year":"2021","unstructured":"Choudhary NS, Duseja A (2021) Genetic and epigenetic disease modifiers: non-alcoholic fatty liver disease (NAFLD) and alcoholic liver disease (ALD). Transl Gastroenterol Hepatol 6:2\u20132. https:\/\/doi.org\/10.21037\/tgh.2019.09.06","journal-title":"Transl Gastroenterol Hepatol"},{"key":"9787_CR24","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1186\/s40001-024-01708-8","volume":"29","author":"SK Mahmoudi","year":"2024","unstructured":"Mahmoudi SK, Tarzemani S, Aghajanzadeh T et al (2024) Exploring the role of genetic variations in NAFLD: implications for disease pathogenesis and precision medicine approaches. Eur J Med Res 29:190. https:\/\/doi.org\/10.1186\/s40001-024-01708-8","journal-title":"Eur J Med Res"},{"key":"9787_CR25","doi-asserted-by":"publisher","first-page":"222","DOI":"10.3390\/ph13090222","volume":"13","author":"R Jamwal","year":"2020","unstructured":"Jamwal R, Barlock BJ (2020) Nonalcoholic fatty liver Disease (NAFLD) and hepatic cytochrome P450 (CYP) enzymes. Pharmaceuticals 13:222. https:\/\/doi.org\/10.3390\/ph13090222","journal-title":"Pharmaceuticals"},{"key":"9787_CR26","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13098-021-00637-4","volume":"13","author":"AS Zahedi","year":"2021","unstructured":"Zahedi AS, Akbarzadeh M, Sedaghati-Khayat B et al (2021) GCKR common functional polymorphisms are associated with metabolic syndrome and its components: a 10-year retrospective cohort study in Iranian adults. Diabetol Metab Syndr 13:20. https:\/\/doi.org\/10.1186\/s13098-021-00637-4","journal-title":"Diabetol Metab Syndr"},{"key":"9787_CR27","doi-asserted-by":"publisher","first-page":"e20555","DOI":"10.1371\/journal.pone.0020555","volume":"6","author":"P Perez-Martinez","year":"2011","unstructured":"Perez-Martinez P, Delgado-Lista J, Garcia-Rios A et al (2011) Glucokinase Regulatory Protein Genetic Variant Interacts with Omega-3 PUFA to influence insulin resistance and inflammation in metabolic syndrome. PLoS ONE 6:e20555. https:\/\/doi.org\/10.1371\/journal.pone.0020555","journal-title":"PLoS ONE"},{"key":"9787_CR28","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s12902-021-00789-4","volume":"21","author":"N Salari","year":"2021","unstructured":"Salari N, Darvishi N, Mansouri K et al (2021) Association between PNPLA3 rs738409 polymorphism and nonalcoholic fatty liver disease: a systematic review and meta-analysis. BMC Endocr Disord 21:125. https:\/\/doi.org\/10.1186\/s12902-021-00789-4","journal-title":"BMC Endocr Disord"},{"key":"9787_CR29","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/1471-2350-11-172","volume":"11","author":"K Hotta","year":"2010","unstructured":"Hotta K, Yoneda M, Hyogo H et al (2010) Association of the rs738409 polymorphism in PNPLA3 with liver damage and the development of nonalcoholic fatty liver disease. BMC Med Genet 11:172. https:\/\/doi.org\/10.1186\/1471-2350-11-172","journal-title":"BMC Med Genet"},{"key":"9787_CR30","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1016\/j.cgh.2023.04.024","volume":"21","author":"C Rosso","year":"2023","unstructured":"Rosso C, Caviglia GP, Birolo G et al (2023) Impact of PNPLA3 rs738409 polymorphism on the development of liver-related events in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 21:3314\u20133321e3. https:\/\/doi.org\/10.1016\/j.cgh.2023.04.024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"9787_CR31","doi-asserted-by":"publisher","unstructured":"Mantovani A, Targher G (2023) PNPLA3 rs738409 polymorphism and kidney dysfunction: an association beyond nonalcoholic fatty liver disease? Metabolism and. https:\/\/doi.org\/10.20517\/mtod.2023.24. Target Organ Damage 3:","DOI":"10.20517\/mtod.2023.24"},{"key":"9787_CR32","unstructured":"Alhussain H (2022) Studies on NAFLD and impact of environmental factors"},{"key":"9787_CR33","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1016\/j.jsps.2021.09.013","volume":"29","author":"LS Binmahfouz","year":"2021","unstructured":"Binmahfouz LS, Bagher AM (2021) Genetic polymorphism of the drug-metabolizing enzyme cytochrome P4502E1 (CYP2E1) in a healthy Saudi population. Saudi Pharm J 29:1355\u20131360. https:\/\/doi.org\/10.1016\/j.jsps.2021.09.013","journal-title":"Saudi Pharm J"},{"key":"9787_CR34","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s00204-007-0200-y","volume":"81","author":"G Ulusoy","year":"2007","unstructured":"Ulusoy G, Arin\u00e7 E, Adali O (2007) Genotype and allele frequencies of polymorphic CYP2E1 in the Turkish population. Arch Toxicol 81:711\u2013718. https:\/\/doi.org\/10.1007\/s00204-007-0200-y","journal-title":"Arch Toxicol"},{"key":"9787_CR35","doi-asserted-by":"publisher","first-page":"e54188","DOI":"10.1371\/journal.pone.0054188","volume":"8","author":"T Zeng","year":"2013","unstructured":"Zeng T, Guo F-F, Zhang C-L et al (2013) Roles of cytochrome P4502E1 gene polymorphisms and the risks of alcoholic liver disease: a Meta-analysis. PLoS ONE 8:e54188. https:\/\/doi.org\/10.1371\/journal.pone.0054188","journal-title":"PLoS ONE"},{"key":"9787_CR36","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/jhg.2010.75","volume":"55","author":"H Onuma","year":"2010","unstructured":"Onuma H, Tabara Y, Kawamoto R et al (2010) The GCKR rs780094 polymorphism is associated with susceptibility of type 2 diabetes, reduced fasting plasma glucose levels, increased triglycerides levels and lower HOMA-IR in Japanese population. J Hum Genet 55:600\u2013604. https:\/\/doi.org\/10.1038\/jhg.2010.75","journal-title":"J Hum Genet"},{"key":"9787_CR37","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s00125-007-0865-z","volume":"51","author":"T Spars\u00f8","year":"2007","unstructured":"Spars\u00f8 T, Andersen G, Nielsen T et al (2007) The GCKR rs780094 polymorphism is associated with elevated fasting serum triacylglycerol, reduced fasting and OGTT-related insulinaemia, and reduced risk of type 2 diabetes. Diabetologia 51:70\u201375. https:\/\/doi.org\/10.1007\/s00125-007-0865-z","journal-title":"Diabetologia"},{"key":"9787_CR38","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13104-020-4891-y","volume":"13","author":"S Mohammadi","year":"2020","unstructured":"Mohammadi S, Farajnia S, Shadmand M et al (2020) Association of rs780094 polymorphism of glucokinase regulatory protein with non-alcoholic fatty liver disease. BMC Res Notes 13:26. https:\/\/doi.org\/10.1186\/s13104-020-4891-y","journal-title":"BMC Res Notes"},{"key":"9787_CR39","doi-asserted-by":"publisher","unstructured":"Nisar T, Arshad K, Abbas Z et al (2023) Prevalence of GCKR rs1260326 Variant in Subjects with Obesity Associated NAFLD and T2DM: A Case-Control Study in South Punjab, Pakistan. J Obes 2023:6661858. https:\/\/doi.org\/10.1155\/2023\/6661858","DOI":"10.1155\/2023\/6661858"},{"key":"9787_CR40","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1007\/s00535-013-0850-x","volume":"49","author":"H-L Tan","year":"2014","unstructured":"Tan H-L, Zain SM, Mohamed R et al (2014) Association of glucokinase regulatory gene polymorphisms with risk and severity of non-alcoholic fatty liver disease: an interaction study with adiponutrin gene. J Gastroenterol 49:1056\u20131064. https:\/\/doi.org\/10.1007\/s00535-013-0850-x","journal-title":"J Gastroenterol"},{"key":"9787_CR41","doi-asserted-by":"publisher","first-page":"2967","DOI":"10.1007\/s10620-014-3279-z","volume":"59","author":"SS Lee","year":"2014","unstructured":"Lee SS, Byoun Y-S, Jeong S-H et al (2014) Role of the PNPLA3 I148M polymorphism in nonalcoholic fatty liver disease and fibrosis in Korea. Dig Dis Sci 59:2967\u20132974. https:\/\/doi.org\/10.1007\/s10620-014-3279-z","journal-title":"Dig Dis Sci"},{"key":"9787_CR42","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.aohep.2018.10.004","volume":"18","author":"DF Mazo","year":"2019","unstructured":"Mazo DF, Malta FM, Stefano JT et al (2019) Validation of PNPLA3 polymorphisms as risk factor for NAFLD and liver fibrosis in an admixed population. Ann Hepatol 18:466\u2013471. https:\/\/doi.org\/10.1016\/j.aohep.2018.10.004","journal-title":"Ann Hepatol"},{"key":"9787_CR43","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1002\/hep.24283","volume":"53","author":"S Sookoian","year":"2011","unstructured":"Sookoian S, Pirola CJ (2011) Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology 53:1883\u20131894. https:\/\/doi.org\/10.1002\/hep.24283","journal-title":"Hepatology"},{"key":"9787_CR44","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1007\/s00439-012-1141-y","volume":"131","author":"SM Zain","year":"2012","unstructured":"Zain SM, Mohamed R, Mahadeva S et al (2012) A multi-ethnic study of a PNPLA3 gene variant and its association with disease severity in non-alcoholic fatty liver disease. Hum Genet 131:1145\u20131152. https:\/\/doi.org\/10.1007\/s00439-012-1141-y","journal-title":"Hum Genet"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-024-09787-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-024-09787-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-024-09787-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T03:50:44Z","timestamp":1738727444000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-024-09787-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,23]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["9787"],"URL":"https:\/\/doi.org\/10.1007\/s11033-024-09787-w","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,23]]},"assertion":[{"value":"30 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Istanbul Geli\u015fim University ethics committee approved this study (ethical code: 77366270-302.08.01-E.12978 date: 16.11.2020). Furthermore, all subjects signed a consent form before to being included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"845"}}